DEF: Journey Medical Corporation to Hold Virtual Annual Meeting on June 24, 2025; Stockholders to Vote on Director Elections, Auditor Ratification, and Officer Exculpation Amendment

Journey Medical Corporation will hold its Annual Meeting of Stockholders virtually on June 24, 2025, to vote on key proposals including the election of directors, ratification of the company's auditor, and an amendment to the company's certificate of incorporation.

Summary

• Journey Medical Corporation will hold its Annual Meeting of Stockholders virtually on June 24, 2025, at 11:00 a.m. Eastern Time.
• Stockholders will vote on the election of six directors for a one-year term, ratification of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025, and approval of the Fourth Amended and Restated Certificate of Incorporation to provide for officer exculpation.
• The record date for determining stockholders eligible to vote is April 25, 2025.
• As of April 14, 2025, directors, executive officers, and affiliated 5% beneficial owners collectively owned approximately 56.49% of the outstanding common stock.
• Stockholders can access the meeting and vote online at www.virtualshareholdermeeting.com/DERM2025.
• The Board of Directors recommends voting FOR all director nominees, FOR the ratification of KPMG LLP, and FOR the approval of the Fourth Amended and Restated Certificate of Incorporation.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting routine corporate governance matters. The sentiment is neutral to positive, reflecting the company's efforts to engage with stockholders and align with best practices.

Positives

• The proposed amendment to the certificate of incorporation aims to protect officers from personal liability, potentially attracting and retaining qualified candidates.
• The virtual format of the annual meeting is expected to encourage broader stockholder participation and reduce costs.
• The board recommends voting for all proposals.

Future Outlook

The document does not contain specific forward-looking financial guidance, but it outlines the matters to be addressed at the Annual Meeting, which will influence the company's governance and operations.

Management Comments

• Claude Maraoui, President, Chief Executive Officer and Director: 'We look forward to virtually seeing you at the Annual Meeting.'
• The Board believes that exculpation provisions empower both directors and officers to exercise their best judgment in furtherance of stockholder interests.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the holding of annual meetings, election of directors, and engagement with stockholders. The proposal to amend the certificate of incorporation to provide for officer exculpation aligns with recent changes in Delaware law and is a trend among public corporations to attract and retain qualified officers.

Comparison to Industry Standards

• Holding virtual annual meetings is becoming increasingly common among public companies to enhance accessibility and reduce costs, aligning with practices seen at companies like Pfizer and Johnson & Johnson.
• The director compensation structure, including cash retainers and equity awards, is consistent with industry benchmarks for companies of similar size and stage, such as those observed at Checkpoint Therapeutics and Mustang Bio.
• The proposal to adopt officer exculpation provisions mirrors actions taken by numerous Delaware-incorporated companies following the 2022 amendment to Section 102(b)(7) of the DGCL, similar to adoptions by companies like Tesla and SpaceX.

Related Party Transactions

• The Company and Fortress entered into an arrangement to share the cost of certain legal, finance, regulatory, and research and development employees.
• For the years ended December 31, 2024 and 2023, Fortress employees have provided services to the Company totaling approximately less than $0.1 million and $0.1 million, respectively.
• As of December 31, 2024 and 2023, the Company had a balance of approximately $0.5 million and $0.2 million, respectively, due to related party on the consolidated balance sheets.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key governance matters, influencing the direction and oversight of the company.
• Employees may benefit from the proposed officer exculpation, which could enhance the company's ability to attract and retain talent.
• The outcome of the auditor ratification vote will impact the company's financial oversight and reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting of Stockholders on June 24, 2025.
• The Board will implement the outcomes of the stockholder votes, including the election of directors and any approved amendments to the certificate of incorporation.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, Officer Exculpation, Corporate Governance, Journey Medical Corporation, Stockholders